title: E2-induced degradation of uterine insulin receptor substrate-2: requirement for an IGF-I-stimulated, proteasome-dependent pathway.
abstract: The insulin receptor substrates are docking proteins that bind various receptor tyrosine kinases and signaling proteins. Previous studies have shown that E2 or progesterone can regulate the relative abundance of insulin receptor substrate-1 and -2 in cells and tissues. For instance, uterine insulin receptor substrate-2 was decreased markedly at 24 h after E2 treatment of mice. In the present study we used various in vivo experimental approaches to examine the mechanism by which E2 influences uterine insulin receptor substrate-2 expression. Uterine insulin receptor substrate-2 mRNA levels were diminished after E2 treatment, but this diminution did not account for the total reduction in insulin receptor substrate-2 protein, suggesting that the E2-induced decrease in insulin receptor substrate-2 is not regulated solely at the mRNA level. Cotreatment with progesterone prevented the E2-stimulated reduction in insulin receptor substrate-2 protein at 24 h after hormone exposure. In addition, MG-132 and epoxomicin, inhibitors of proteasomal protease activity, inhibited the E2-induced decrease in uterine insulin receptor substrate-2 protein levels, and this correlated to an increase in uterine protein ubiquitination. Insulin receptor substrate-2 protein was diminished in uteri of E2-treated insulin receptor substrate-1-null mutant mice, but not in E2-treated IGF-I-null mutant mice. Furthermore, E2-induced diminution of uterine insulin receptor substrate-2 protein was only partially inhibited in the presence of wortmannin, a PI3K inhibitor. Collectively, these data suggest that the E2-induced decrease in uterine insulin receptor substrate-2 requires IGF-I signaling, is not dependent solely on insulin receptor substrate-1 and PI3K, and is blocked by progesterone as well as by pharmacological inhibition of proteasomal protease activity. We speculate that the IGF-I-activated IGF-I receptor, in response to E2, directly or indirectly modifies insulin receptor substrate-2, probably through phosphorylation, leading to ubiquitination and subsequent degradation of this docking protein by the proteasome. This degradation could be a regulatory step to inhibit insulin receptor substrate-2-dependent signaling in the uterus.
authors.affiliation: Hormones and Cancer Group, Laboratory of Molecular Carcinogenesis, National Institute of Environmental and Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: Richards
authors.forename: D M
authors.initials: DM
authors.lastname: Klotz
authors.forename: M R
authors.initials: MR
authors.lastname: Bush
authors.forename: D K
authors.initials: DK
authors.lastname: Walmer
authors.forename: R P
authors.initials: RP
authors.lastname: DiAugustine
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D003546:Cysteine Endopeptidases / Q000502:physiology*; D004958:Estradiol / Q000494:pharmacology*; D004971:Estrus / Q000502:physiology; D005260:Female; D006801:Humans; D055504:Insulin Receptor Substrate Proteins; D007334:Insulin-Like Growth Factor I / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D047908:Intracellular Signaling Peptides and Proteins; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout / Q000235:genetics; D009097:Multienzyme Complexes / Q000502:physiology*; D010053:Ovary / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010750:Phosphoproteins / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D011374:Progesterone / Q000494:pharmacology; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012016:Reference Values; D014452:Ubiquitins / Q000378:metabolism; D014599:Uterus / Q000378:metabolism*; D000077191:Wortmannin
chemical_list: D000730:Androstadienes; C526297:IRS2 protein, human; D055504:Insulin Receptor Substrate Proteins; D047908:Intracellular Signaling Peptides and Proteins; C526298:Irs2 protein, mouse; D009097:Multienzyme Complexes; D010726:Phosphodiesterase Inhibitors; D010750:Phosphoproteins; D011506:Proteins; D012333:RNA, Messenger; D014452:Ubiquitins; D011374:Progesterone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D000077191:Wortmannin